Image

Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis

Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis

Recruiting
16-55 years
All
Phase N/A

Powered by AI

Overview

This research concerns the study of language disorders of patients present in the spectrum of psychosis. It is indeed accepted that psychotic disorders are associated with language difficulties, which are only poorly highlighted thanks to reusable tools in clinical practice. These language disorders impact communication, and concern many linguistic domains, thus covering phonology, lexicon, semantics, morphosyntax and pragmatics. It therefore seems relevant to characterize these language disorders and to assess to what extent they interact with the other symptoms of the pathology, in particular the course of the thought disorder and the neuropsychological symptoms. In addition, this study is particularly interested in the interactions between working memory capacities and those related to syntax. It is intended for different patients suffering from psychotic disorders of different intensities, treated in the Psychotherapeutic Center of Nancy. Patients suffering from at-risk mental state (ARMS), first episode of psychosis (FEP) or schizophrenia will benefit from a complete language assessment, evaluating each domain mentioned above, on the expressive and understanding sides. The results of the language assessment will be compared with those of a control group in the same tests. They will also be analyzed with regard to the neuropsychological and psychiatric elements noted in the patient's medical file, in order to highlight possible associations between language skills, neuropsychological and psychiatric symptoms in this patient population.

Eligibility

Inclusion Criteria:

  • All Groups:
    • Patient affiliated or entitled to a social security scheme
    • Patient having received informed information on the study and having co-signed, with the investigator, a consent to participate in the study
    • For minor participants, at least one of the parents or holders of parental authority having been informed of the study, having received the information note relating to it and not having objected to the participation of his or her child
    • Native language: French
  • ARMS and FEP Patient Group:
    • Age between 16 and 35 years old
    • Present the criteria for EMRP or FEP as defined by the Comprehensive Assessment of At Risk Mental State (CAARMS) or present the criteria for Disorders of the course of thought to the items of the Schizophrenia Proneness Instrument (SPI-A)
  • Patients with schizophrenia group:
    • Age between 16 and 55 years old
    • Patient with diagnostic criteria for schizophrenia, as defined by DSM V (American Psychiatric Association, 2015)
    • Present the criteria for Disorganization of Speech and Formal Thought Disorder as defined by the Thinking, Language and Communication (TLC) Rating Scale.
  • Healthy Volunteers Group:
    • Age between 16 and 55 years old
    • Parental authorization (of both parents) to participate in the study for minor patients

Exclusion Criteria:

  • All groups:
    • Pregnant, parturient or nursing mother
    • Person deprived of liberty by a judicial or administrative decision
    • Person in a life-threatening emergency
    • Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
    • Adult person unable to express their consent and who is not the subject of a legal protection measure
    • Impairment of the subject making it difficult, if not impossible, for them to participate in the trial or to understand the information given to them
    • Abuse or dependence of any substance according to DSM V criteria excluding cannabis
  • Healthy Volunteers Group:
    • Evolving psychiatric pathology (axis I of the DSM IV, measured at the MINI) excluding anxiety disorder
    • Presence of developmental disorder of oral language or written language revealed on clinical examination.

Study details
    Psychosis
    Schizophrenia
    At-risk Mental State
    Language Disorders

NCT06036316

Centre Psychothérapique de Nancy

18 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.